Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$18.86 ▼ -0.08
(-0.42%)
MKT CAP: $3.01B • VOL: 1.24M
52W L $14 52W H $27
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$16
MEDIAN
$21
MEAN
$22
HIGH
$26
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE DNLI TAPE
DNLI // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $22.82 | $21.69 | 2025-02-14 | $17.16 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $23.76 | $22.25 | 2025-02-06 | $17.73 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $21.50 | $20.75 | 2025-01-29 | $18.11 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $19.24 | — | 2025-01-17 | $18.48 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $16.60 | $17.92 | 2025-01-09 | $16.79 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $22.44 | $19.61 | 2024-12-18 | $16.41 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $18.29 | $19.05 | 2024-12-04 | $17.54 | -4.3% | 48% | C |